FDA lifts hold as Rocket Pharmaceuticals (RCKT) pivotal RP-A501 Danon trial resumes

Rhea-AI Filing Summary

Rocket Pharmaceuticals filed a current report stating that the U.S. Food and Drug Administration has lifted the clinical hold on its pivotal Phase 2 trial of RP‑A501, a gene therapy candidate for the treatment of Danon disease. This means the planned pivotal study can now proceed under FDA oversight. The company also issued a press release about this development, which is attached as an exhibit to the report.

Positive

• FDA lifts clinical hold on pivotal RP‑A501 trial, allowing Rocket Pharmaceuticals to move forward with its Phase 2 study in Danon disease, a key step in advancing this gene therapy program.

Negative

• None.

Insights

Biotech and regulatory affairs analyst

FDA cleared Rocket’s pivotal RP‑A501 trial to resume after lifting a clinical hold.

The report states that the U.S. Food and Drug Administration has lifted the clinical hold on Rocket Pharmaceuticals’ pivotal Phase 2 trial of RP‑A501 for Danon disease. A clinical hold pauses trial activities, so removal is a key regulatory step for advancing this gene therapy program.

The trial is described as pivotal, indicating it is designed to generate data that may support a future marketing application if successful. Resumption of this study restores a formal development path for RP‑A501 in Danon disease. A related company press release, dated August 20, 2025, is attached as an exhibit, providing further detail on the announcement.

false000128189500012818952025-08-202025-08-20

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 20, 2025

Rocket Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-36829	04-3475813
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

9 Cedarbrook Drive, Cranbury, NJ		08512
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (646) 440-9100

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, $0.01 par value	RCKT	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On August 20, 2025, Rocket Pharmaceuticals, Inc. (the “Company”) announced that the U.S. Food and Drug Administration has lifted the clinical hold on the Company’s pivotal Phase 2 trial of RP-A501 for the treatment of Danon disease.

A copy of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this report by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1	Press Release of Rocket Pharmaceuticals, Inc. dated August 20, 2025.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Rocket Pharmaceuticals, Inc.
Date: August 20, 2025	By:	/s/ Martin Wilson
		Martin Wilson
		General Counsel and Chief Corporate Officer, SVP

FAQ

What did Rocket Pharmaceuticals (RCKT) announce regarding its RP-A501 trial?

Rocket Pharmaceuticals announced that the U.S. Food and Drug Administration lifted the clinical hold on its pivotal Phase 2 trial of RP-A501 for Danon disease. This regulatory change allows the planned trial activities to proceed under FDA oversight and resume the program’s clinical progress.

What is the significance of the FDA lifting a clinical hold for RCKT?

Lifting a clinical hold means the FDA has cleared the pivotal Phase 2 RP-A501 trial to proceed. This removes a formal pause on clinical work in Danon disease and restores a development pathway that could generate data to support future regulatory submissions if successful.

Which Rocket Pharmaceuticals program is affected by this 8-K filing?

The filing focuses on RP-A501, Rocket Pharmaceuticals’ gene therapy candidate for Danon disease. The U.S. Food and Drug Administration has lifted the clinical hold on its pivotal Phase 2 trial, enabling Rocket to continue advancing this specific program within its broader rare disease pipeline.

How did Rocket Pharmaceuticals disclose the FDA decision on RP-A501?

Rocket Pharmaceuticals disclosed the FDA’s decision in a current report and attached a press release as Exhibit 99.1. The report states that the agency lifted the clinical hold on the pivotal Phase 2 RP-A501 trial for Danon disease, and the press release provides additional related information.

Does the 8-K mention any other financial or operational changes for RCKT?

The report centers on the FDA lifting the clinical hold on the pivotal Phase 2 RP-A501 trial in Danon disease. It references an accompanying press release and standard administrative details, without describing additional financial metrics or separate operational initiatives in the provided content.